Business Context and Reporting Period
Molina Healthcare, Inc. (MOH) filed a Form 8-K on November 13, 2024, to disclose a planned private offering of debt securities. The filing includes supplemental financial data provided to potential investors covering the years ended December 31, 2021 through 2023, and the nine and twelve months ended September 30, 2024.
Key Financial Metrics
The filing provides Net Income and Adjusted EBITDA figures in millions of dollars. Revenue, cash flow, debt balances, and liquidity metrics are not explicitly detailed in this specific filing text.
| Period | Net Income | EBITDA | Adjusted EBITDA |
|---|---|---|---|
| Year Ended Dec 31, 2021 | $659 | $1,126 | $1,325 |
| Year Ended Dec 31, 2022 | $792 | $1,349 | $1,709 |
| Year Ended Dec 31, 2023 | $1,091 | $1,744 | $1,934 |
| Nine Months Ended Sep 30, 2023 | $875 | $1,385 | $1,518 |
| Nine Months Ended Sep 30, 2024 | $928 | $1,465 | $1,625 |
| Twelve Months Ended Sep 30, 2024 | $1,144 | $1,824 | $2,041 |
Debt Offering: The Company intends to privately offer $500 million aggregate principal amount of senior notes due 2033.
Material Changes and Trends
- Profitability Growth: Net income increased from $1,091 million in 2023 to $1,144 million for the twelve months ended September 30, 2024.
- Adjusted EBITDA: Adjusted EBITDA rose to $2,041 million for the twelve months ended September 30, 2024, compared to $1,934 million for the full year 2023.
- Non-Recurring Items: The 2022 period included $208 million in impairment charges related to reducing leased real estate footprint. The 2023 and 2024 periods included adjustments for litigation costs, termination benefits, and credit losses related to Texas risk pool insolvency.
Guidance, Risks, and Unusual Items
Offering Details: The $500 million senior notes are to be sold to qualified institutional buyers under Rule 144A and to persons outside the U.S. under Regulation S. The offering is subject to market and other conditions.
Non-GAAP Limitations: Management notes that EBITDA and Adjusted EBITDA exclude interest, taxes, capital expenditures, and working capital needs. They should not be viewed as discretionary cash available for investment.
Unusual Items: Adjustments to reach Adjusted EBITDA include stock-based compensation, acquisition-related expenses, and specific non-recurring charges such as litigation costs and credit losses on risk adjustment receivables.
Investor Verification Checklist
- Verify the final pricing and interest rate of the $500 million senior notes due 2033 once the offering is completed.
- Review the full text of the press release (Exhibit 99.1) for specific use of proceeds.
- Confirm the impact of the Texas risk pool insolvency on future receivables and credit loss provisions.
- Compare the non-GAAP Adjusted EBITDA figures against GAAP Net Income to assess the magnitude of recurring vs. non-recurring adjustments.
- Check subsequent filings for the final closing date of the debt offering.